Costs and Barriers of Cancer Screening After Positive Genetic Testing: Are Actionable Mutations Becoming “Unactionable”?

Authors: Ryan M. Kahn MD, MHS, Sushmita Gordhandas MD, Emeline Aviki MD, MBA, and Kara Long Roche MD, MSc
View More View Less

Disclosures: The authors have disclosed that they have no potential conflicts of interest.

Correspondence: Kara Long Roche, MD, MSc, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: longrock@mskcc.org
  • 1.

    Offit K, Tkachuk KA, Stadler ZK, et al. Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening. J Clin Oncol 2020;38:13981408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Daly MB, Pal T, Berry MP, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:77102.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Weiss M, Gupta S, Burke CA, et al. Genetic/Familial High-Risk Assessment: Colorectal Version 1.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:11221132.

    • Search Google Scholar
    • Export Citation
  • 4.

    USPSTF Recommendations Development Process. Accessed January 30, 2022. Available at: https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-recommendations-development-process

  • 5.

    FORCE. Medicare and Medicaid cover specific cancer screenings. Accessed January 30, 2022. Available at: https://www.facingourrisk.org/support/insurance-paying-for-care/screening-and-prevention/cancer-screening/medicare-and-medicaid

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 917 917 917
PDF Downloads 639 639 639
EPUB Downloads 0 0 0